The online version of this article (doi:10.1186/s12891-015-0732-x) contains supplementary material, which is available to authorized users.
Kengo Takahashi, Takao Setoguchi, Hiroki Tawaratsumida contributed equally to this work.
The authors declare that they have no competing interests.
TS and H. Tominaga conceived and designed the study. KT, H. Tawaratsumida, YA, SS, NA, MA, HO, TM and NS collected data. HK, MH, MY, SN, YI and TS analyzed the data. TS and SK wrote the manuscript. All authors read and approved the final manuscript.
Osteoporosis is a complication of rheumatoid arthritis (RA). We identified risk factors for osteoporosis during treatment with biologics.
Femoral neck bone mineral density (BMD) was measured in 186 patients with biologics-treated RA. We compared the characteristics of those with BMD ≥70 % of young adult mean (YAM) and those with BMD <70 % of YAM, and undertook multivariable logistic regression analysis to identify risk factors for bone loss.
Mean age and disease duration, the proportion of females, scores in the Modified Health Assessment Questionnaire and history of vertebral fracture were significantly greater in the BMD <70 % of YAM group, but body mass index (BMI) was significantly lower in the BMD <70 % of YAM group. There was no significant difference between the groups in terms of other biomarkers of RA activity, the proportion treated with methylprednisolone, or the duration or choice of biologics. The proportions of patients treated with anti-osteoporosis drugs and parathyroid hormone were significantly higher in the BMD <70 % of YAM group. In the multivariable analysis, advanced age, female, longer disease duration, history of past thoracic or lumbar vertebral fracture, higher Steinbrocker classification and lower BMI were significant factors for BMD <70 % of YAM.
We identified risk factors for bone loss in patients with RA treated with biologics. Before suppression of disease activity by biologics, bone loss might already be advanced.
We recommend that patients with RA who possess these risk factors be considered for earlier and more intense treatment to prevent bone loss, as well as addressing RA disease progression.
Additional file 1: Table S1. Univariate analysis of factors potentially associated with low bone mineral density in patients with rheumatoid arthritis treated with biologics. (DOCX 14 kb)12891_2015_732_MOESM1_ESM.docx
Soen S. Diagnostic criteria for primary osteoporosis : year 2012 revision. Clin Calcium. 2014;24(3):323–9. doi:CliCa1403323329. PubMed
Hagino H. Revised osteoporosis diagnostic criteria and Japanese practice guideline on osteoporosis. Clin Calcium. 2014;24(1):11–8. doi:CliCa14011118. PubMed
Hofbauer LC, Heufelder AE. The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum. 2001;44(2):253–9. doi: 10.1002/1529-0131(200102)44:2<253::AID-ANR41>3.0.CO;2-S. CrossRefPubMed
Dolan AL, Moniz C, Abraha H, Pitt P. Does active treatment of rheumatoid arthritis limit disease-associated bone loss? Rheumatology (Oxford). 2002;41(9):1047–51. CrossRef
Jensen TW, Hansen MS, Horslev-Petersen K, Hyldstrup L, Abrahamsen B, Langdahl B, et al. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. Ann Rheum Dis. 2014;73(6):1123–9. doi: 10.1136/annrheumdis-2012-203171. CrossRefPubMed
Guler-Yuksel M, Klarenbeek NB, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van der Kooij SM, Gerards AH, et al. Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis. Arthritis Res Ther. 2010;12(3):R96. doi: 10.1186/ar3025. CrossRefPubMedPubMedCentral
Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum. 2000;43(10):2143–51. doi: 10.1002/1529-0131(200010)43:10<2143::AID-ANR1>3.0.CO;2-S. CrossRefPubMed
Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999;163(3):1521–8. PubMed
Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(11):1495–9. doi: 10.1136/ard.2005.044198. CrossRefPubMedPubMedCentral
Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C, Miossec P. A 1-year case–control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther. 2007;9(3):R61. doi: 10.1186/ar2219. CrossRefPubMedPubMedCentral
- Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics
- BioMed Central
Neu im Fachgebiet Orthopädie und Unfallchirurgie
Mail Icon II